Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. - RIIP - Réseau International des Instituts Pasteur Access content directly
Journal Articles American Journal of Transplantation Year : 2013

Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.

Abstract

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, we tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury. We performed a case-control study in which we compared anti-LG3 IgG titers in kidney transplant recipients with AVR (n=15) versus those with acute tubulo-interstitial rejection (ATIR) (n=15) or stable graft function (n=30). Patients who experienced AVR had elevated anti-LG3 titers pre and posttransplantation compared to subjects with ATIR or stable graft function (p<0.05 for both mediators). Elevated pretransplant anti-LG3 titers (OR: 4.62, 95% CI: 1.08-19.72) and pretransplant donor-specific antibodies (DSA) (OR 4.79, 95% CI: 1.03-22.19) were both independently associated with AVR. To address the functional role of anti-LG3 antibodies in AVR, we turned to passive transfer of anti-LG3 antibodies in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice. Neointima formation, C4d deposition and allograft inflammation were significantly increased in recipients of an ischemic aortic allograft passively transferred with anti-LG3 antibodies. Collectively, these data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodeling.

Dates and versions

pasteur-01130364 , version 1 (11-03-2015)

Identifiers

Cite

H Cardinal, M Dieudé, N Brassard, S Qi, N Patey, et al.. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.. American Journal of Transplantation, 2013, 13 (4), pp.861-74. ⟨10.1111/ajt.12168⟩. ⟨pasteur-01130364⟩

Collections

RIIP INRS-IAF
25 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More